RacetamsEvidence & Dosage
Piracetam, aniracetam, oxiracetam — gray-area nootropics, weak evidence.
Evidence at a glance
- Total studies
- 107
- With abstract
- 50
- Meta / Systematic / RCT
- 0
- Highly cited
- 50
- Publication years
- 1992–2026
Racetams in the context of Cognition
This topic is part of our "Cognition" world. There you'll find methodology, evidence and the highest-impact levers — plus the order in which they sensibly build on each other.
Go to CognitionTop studies on Racetams
Ranked by influential-citation count and publication year.
Glutamate as a neurotransmitter in the brain: review of physiology and pathology.
The Journal of nutrition2000200 influential citationsGlutamate is the principal excitatory neurotransmitter in brain. Our knowledge of the glutamatergic synapse has advanced enormously in the last 10 years, primarily through application of molecular biological techniques to the study of…
Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2024200 influential citationsN-methyl-D-aspartate (NMDA) receptors mediate a slow component of excitatory synaptic transmission, are widely distributed throughout the central nervous system, and regulate synaptic plasticity. NMDA receptor modulators have long been…
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.
CNS Drugs2022n=3,182review168 influential citationsThe developmental and epileptic encephalopathies encompass a group of rare syndromes characterised by severe drug-resistant epilepsy with onset in childhood and significant neurodevelopmental comorbidities. The latter include intellectual…
NMDA Receptor Antagonists: Emerging Insights into Molecular Mechanisms and Clinical Applications in Neurological Disorders.
Pharmaceuticals (Basel, Switzerland)2024141 influential citationsNeurodegenerative disorders (NDs) include a range of chronic conditions characterized by progressive neuronal loss, leading to cognitive, motor, and behavioral impairments. Common examples include Alzheimer's disease (AD) and Parkinson's…
Clinical experience with excitatory amino acid antagonist drugs.
Stroke1995139 influential citations<h4>Background</h4>Excitotoxic damage due to excess release of neuronal glutamate is hypothesized to play a pivotal role in the pathogenesis of focal cerebral ischemia. Drugs that antagonize excitatory amino acid function are consistently…
Novel psychoactive substances of interest for psychiatry.
World psychiatry : official journal of the World Psychiatric Association (WPA)2015109 influential citationsNovel psychoactive substances include synthetic cannabinoids, cathinone derivatives, psychedelic phenethylamines, novel stimulants, synthetic opioids, tryptamine derivatives, phencyclidine-like dissociatives, piperazines, GABA-A/B receptor…
Glutamate as a therapeutic target in psychiatric disorders.
Molecular psychiatry2004108 influential citationsGlutamate is the primary excitatory neurotransmitter in the mammalian brain. Glutamatergic neurotransmission may be modulated at multiple levels, only a minority of which are currently being exploited for pharmaceutical development.…
Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines.
Trends in pharmacological sciences1993100 influential citationsNMDA and non-NMDA (AMPA/kainate) antagonists have potential in the treatment of a diverse group of neurological disorders associated with excessive activation of excitatory amino acid receptors. Here Michael Rogawski reviews recent…
Cognitive enhancement as a treatment for drug addictions.
Neuropharmacology2013n=1,16194 influential citationsDrug addiction continues to be an important public health problem, with an estimated 22.6 million current illicit drug users in the United States alone. For many addictions, including cocaine, methamphetamine, and marijuana addiction,…
Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties.
Journal of neural transmission. Supplementum199487 influential citationsThe pharmacological inhibition of excitatory amino acid neurotransmission has evolved to be a major topic in neuropharmacology since enhanced synaptic action of glutamate and possibly other related neurotransmitters has been suggested to…
More topics in Cognition
Bacopa Monnieri
Memory, Bacosides, Long-term Effect and Tolerance
Acetyl-L-Carnitine (ALCAR)
Mitochondria, neuroprotection, and energy metabolism.
Acetylcholine
Memory, attention, REM sleep, choline sources.
Active Recall
Retrieval over rereading — a scientifically superior way to learn.
Alpha-GPC
Choline source for acetylcholine and cognitive performance
Binaural Beats
Auditory frequency stimulation — mixed evidence.
Blood-Brain Barrier
Selective permeability, substance passage, inflammation-driven leakiness.
Brain Fog
Multifactorial: sleep, blood sugar, inflammation, thyroid, long COVID.
Caffeine
Adenosine-receptor antagonist, tolerance, timing, half-life, genetics.
Citicoline (CDP-Choline)
Phospholipid synthesis, ADHD, and neurological applications.
Creatine
More than just sport: memory, sleep deprivation, vegan deficits.
Deep Work
Focused, distraction-free work as a trainable skill.
Dopamine
Motivation, reward, movement, learning — the brain's core reward chemistry.
Dopamine Detox
A popular trend without strong scientific backing — what still holds up.
Exercise & Learning
BDNF, the hippocampus, cognitive reserve — exercise makes you sharper.
Flow State
Optimal state of consciousness during full immersion — conditions and triggers.
Ginkgo Biloba
Microcirculation, memory, and dementia interactions.
Glucose vs Ketones
The brain's fuel sources, ketogenic adaptation, cognitive effects.
Histamine
Wakefulness, allergy, histamine intolerance and brain fog.
L-Theanine
Alpha waves, relaxation without sedation, caffeine synergy.
Related topics from other worlds
SARMs
Selective androgen receptor modulators — doping, off-label, liver risk.
VO2max Training
Intervals, VO2max, cardiovascular ceiling and protocols.
Compression Recovery
Compression garments, lymphatic drainage, and recovery studies.
Foam Rolling
Self-myofascial release, ROM, and recovery effects.
NSDR
Structured deep relaxation — a term coined by Andrew Huberman.
Sleep as Recovery
Sleep architecture for muscular and neuronal repair.